Real-time quantitative polymerase chain reaction detection of minimal residual disease in acute lymphoblastic leukemia: a single-center experience

2016 ◽  
Vol 1 (3) ◽  
pp. 31 ◽  
Author(s):  
EmanM Nagiub Abdelsalam ◽  
Shabaan Redwaan ◽  
Hesham Abdelraheem ◽  
TaghreedK Eldin ◽  
Hosny Badrawy
Keyword(s):  
Polymerase Chain Reaction ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Quantitative Polymerase Chain Reaction ◽  
Single Center ◽  
Polymerase Chain Reaction Detection ◽  
Chain Reaction ◽  
Single Center Experience ◽  
Polymerase Chain ◽  
Minimal Residual

scholarly journals CURRENT STRATEGIES FOR THE DETECTION OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

2016 ◽  
Vol 8 ◽  
pp. 2016024 ◽  
Author(s):  
Juliana Maria Camargos Rocha ◽  
Sandra Guerra Xavier ◽  
Marcelo Eduardo Lima Souza ◽  
Juliana Godoy Assumpção ◽  
Mitiko Murao ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Polymerase Chain Reaction ◽  
Acute Lymphoblastic Leukemia ◽  
High Risk ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Quantitative Polymerase Chain Reaction ◽  
Chain Reaction ◽  
Polymerase Chain ◽  
Minimal Residual

Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Current treatment strategies for childhood ALL result in long term remission for approximately 90% of patients. However, therapeutic response is worse among those who relapse. Several risk stratification approaches based on clinical and biological aspects have been proposed in order to intensify treatment in patients with high risk of relapse and reduce toxicity on those with greater probability of cure.The detection of residual leukemic cells (minimal residual disease, MRD) is the most important prognostic factor to identify high risk patients, allowing redefinition of chemotherapy. In the last decades, several standardized research protocols evaluated MRD using immunophenotyping by flow cytometry and/or real time quantitative polymerase chain reaction at different time points during treatment. Both methods are highly sensitive (10-3 a 10-5), but expensive, complex, and, because of that, require qualified staff and frequently are restricted to reference centers.The aim of this article was to review technical aspects of immunophenotyping by flow cytometry and real time quantitative polymerase chain reaction to evaluate MRD in ALL. 

scholarly journals Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia

2020 ◽  
Vol 21 (3) ◽  
pp. 1054 ◽  
Author(s):  
Kruse ◽  
Abdel-Azim ◽  
Kim ◽  
Ruan ◽  
Phan ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Quantitative Polymerase Chain Reaction ◽  
Leukemia Cell ◽  
Chain Reaction ◽  
Phenotypic Marker ◽  
Polymerase Chain ◽  
Minimal Residual

Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia cell population that gives rise to relapse of the disease. The detection of MRD is critical for predicting the outcome and for selecting the intensity of further treatment strategies. The development of various new diagnostic platforms, including next-generation sequencing (NGS), has introduced significant advances in the sensitivity of MRD diagnostics. Here, we review current methods to diagnose MRD through phenotypic marker patterns or differential gene patterns through analysis by flow cytometry (FCM), polymerase chain reaction (PCR), real-time quantitative polymerase chain reaction (RQ-PCR), reverse transcription polymerase chain reaction (RT-PCR) or NGS. Future advances in clinical procedures will be molded by practical feasibility and patient needs regarding greater diagnostic sensitivity.

Sign in / Sign up

Export Citation Format

Share Document